Vertaling van "results of between " (Nederlands → Frans) :

The initial results of the “Active pharmacovigilance” project have been very encouraging given that the number of reports received by the FAMHP has more or less doubled between 2007 and 2008.
The initial results of the “Active pharmacovigilance” project have been very encouraging given that the number of reports received by the FAMHP has more or less doubled between 2007 and 2008.

Moreover, there is a connection between this type of abusive behaviour and depression, with the latter either its cause (in that case, the abuse is the result of the individual’s seeking a solution in “self-medication”) or its consequence (with excessive consumption leading to depression).
De plus, ce type de comportement d’abus n’est pas sans lien avec la dépression, qu’elle en soit la cause (l’abus est alors la « solution d’auto-médication » de l’individu) ou la conséquence (la consommation excessive induisant une dépression).

It is essential for the FAMHP’s communication actions to be the outcome of mutual harmonisation between the relevant departments and services, with the results being communicated unambiguously.
It is essential for the FAMHP’s communication actions to be the outcome of mutual harmonisation between the relevant departments and services, with the results being communicated unambiguously.

Considerable attention was focused in 2007 on increased cooperation on the part of the FAMHP with the ethics committees, with the following results: ●● An interactive website with a web application that makes possible the “simple” management of communication actions between the different ethics committees, the FAMHP, the sponsors and researchers, and also monitors the different stages in the evaluation of each application by the ethics committees ●● Systematic consultation for the more complex scientific applications ●● Further optimisation of the functioning of
Considerable attention was focused in 2007 on increased cooperation on the part of the FAMHP with the ethics committees, with the following results: ●● An interactive website with a web application that makes possible the “simple” management of communication actions between the different ethics committees, the FAMHP, the sponsors and researchers, and also monitors the different stages in the evaluation of each application by the ethics committees ●● Systematic consultation for the more complex scientific applications ●● Further optimisation of the functioning of

3.2.2 Confirmation of oxacillin-resistance Oxacillin-resistance must be confirmed with another method than the screening method at least once per patient and in case of any atypical results or discrepancy between the methods mentioned above.
3.2.2 Confirmation de la résistance à l’oxacilline La résistance à l’oxacilline doit être confirmée par une autre méthode que la méthode de dépistage au moins une fois par patient et en cas de résultats atypiques ou de discordance entre les méthodes mentionnées ci-dessus.

Taxes on the adjustments between IFRS and core results take into account the tax rate applicable in the jurisdiction where the adjustment arises.
Les impôts relatifs aux ajustements entre les résultats IFRS et core tiennent compte des taux d’imposition des juridictions dans lesquelles ces ajustements sont enregistrés.

5 Taxes on the adjustments between IFRS and core results take into account the tax rate applicable in the jurisdiction where the adjustment arises.
5 Les impôts relatifs aux ajustements entre les résultats IFRS et les résultats core tiennent compte du taux d’imposition applicable dans la juridiction où l’ajustement a lieu.

Famvir litigation In February 2010, Novartis and Teva have reached a settlement ending the US patent litigation between them relating to Famvir, a therapy for viral infections, after a trial against Teva in November 2009 resulted in a jury verdict in favor of Novartis that the compound patent was valid and enforceable and an advisory verdict that there was no inequitable conduct.
Litige portant sur Famvir En février 2010, Novartis et Teva sont parvenus à un règlement mettant fin au litige sur le brevet américain qui les opposait dans le cas de Famvir, un traitement des infections virales. Un procès contre Teva, qui s’est terminé en novembre 2009 par un verdict du jury en faveur de Novartis, a conclu que le brevet de la molécule était valide et exécutoire et par un verdict consultatif confirmant que la conduite de la société n’avait pas été inéquitable.

Famvir patent litigation In February 2010, Novartis and Teva reached a settlement ending the US patent litigation between them relating to Famvir after a trial against Teva in November 2009 had resulted in a jury verdict in favor of Novartis.
Famvir : litige sur le brevet En février 2010, Novartis et Teva ont conclu un règlement mettant fin au litige portant sur le brevet de Famvir aux Etats-Unis. Celui-là fait suite au procès intenté par Novartis à Teva qui s’est terminé en novembre 2009 par un verdict du jury en faveur de Novartis.

As a result of the natural hedging effect that partially exists between revenues and costs, the impact on operating income of current rates, if they prevail for the remainder of the year, is expected to be broadly neutral.
Sur l'année un effet légèrement négatif est attendu en raison de l’effet naturel de couverture qui existe en partie entre les produits et les charges, l’impact des taux de change actuels sur le résultat opérationnel devrait être globalement neutre s’ils n'évoluent plus d'ici à la fin de l’année.